Literature DB >> 15154828

The periodic safety update report as a pharmacovigilance tool.

Michael J Klepper1.   

Abstract

The periodic safety update report for marketed drugs (PSUR) was designed to be a stand-alone document that allows a periodic but comprehensive assessment of the worldwide safety data of a marketed drug or biological product. The PSUR can be an important source for the identification of new safety signals, a means of determining changes in the benefit-risk profile, an effective means of risk communication to regulatory authorities and an indicator for the need for risk management initiatives, as well as a tracking mechanism monitoring the effectiveness of such initiatives. For these reasons, the PSUR can be an important pharmacovigilance tool. Numerous steps are involved in the PSUR process including: intake of adverse drug reaction information, case processing, data retrieval, data analysis, and medical review and risk assessment. These processes are heavily reliant on the availability of adequate resources. An overarching principle throughout the PSUR process is the need for a proactive approach in order to identify the critical steps in the process and to have a clear understanding of the consequences of any critical 'mis-step'. With this information comes appropriate planning, building quality into each step of the PSUR process and monitoring performance will maximise the likelihood of generating a quality report. Any failure of a key PSUR process will have the opposite effect - a poor quality report that will give little insight into emerging safety signals or provide misleading information that can adversely affect public health. A pragmatic approach that will avoid or minimise these pitfalls includes the following: adequate resource planning, training, development of 'scripts' designed to maximise the capture of key information for medically important reactions, standardised and harmonised Medical Dictionary for Regulatory Activities (MedDRA) coding procedures, pre-specified search criteria for data retrieval, ongoing medical review, and metrics to evaluate the effectiveness and efficiencies of these processes. With these quality measures in place, the utility of the PSUR as an effective pharmacovigilance tool is enhanced.

Mesh:

Year:  2004        PMID: 15154828     DOI: 10.2165/00002018-200427080-00008

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  10 in total

1.  A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

Authors:  M Lindquist; M Ståhl; A Bate; I R Edwards; R H Meyboom
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

2.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

3.  Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Authors:  Ana Szarfman; Stella G Machado; Robert T O'Neill
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Pharmacoepidemiology: current status, prospects, and problems.

Authors:  B L Strom; P Tugwell
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

5.  Drug utilization study methodologies: national and international perspectives.

Authors:  J Serradell; D C Bjornson; A G Hartzema
Journal:  Drug Intell Clin Pharm       Date:  1987-12

6.  Rhode Island physicians' recognition and reporting of adverse drug reactions.

Authors:  H D Scott; S E Rosenbaum; W J Waters; A M Colt; L G Andrews; J P Juergens; G A Faich
Journal:  R I Med J       Date:  1987-07

7.  An evaluation of spontaneous adverse drug reaction monitoring systems.

Authors:  R M Sachs; E A Bortnichak
Journal:  Am J Med       Date:  1986-11-28       Impact factor: 4.965

8.  Factors determining physician reporting of adverse drug reactions. Comparison of 2000 spontaneous reports with surveillance studies at the Massachusetts General Hospital.

Authors:  J Koch-Weser; V W Sidel; R H Sweet; P Kanarek; A E Eaton
Journal:  N Engl J Med       Date:  1969-01-02       Impact factor: 91.245

Review 9.  False-positives in spontaneous reporting: should we worry about them?

Authors:  B Begaud; Y Moride; P Tubert-Bitter; A Chaslerie; F Haramburu
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

10.  Standardized assessment of drug-adverse reaction associations--rationale and experience.

Authors:  J Venulet; A Ciucci; G C Berneker
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-09
  10 in total
  5 in total

Review 1.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  How to apply the human factor to periodic safety update reports.

Authors:  Brian David Edwards; Giovanni Furlan
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

Review 3.  Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).

Authors:  Matthias Oelke; Klaus Becher; David Castro-Diaz; Emmanuel Chartier-Kastler; Mike Kirby; Adrian Wagg; Martin Wehling
Journal:  Age Ageing       Date:  2015-06-23       Impact factor: 10.668

Review 4.  Pharmacovigilance system in Saudi Arabia.

Authors:  Thamir M Alshammari; Mohammed Alshakka; Hisham Aljadhey
Journal:  Saudi Pharm J       Date:  2016-09-30       Impact factor: 4.330

Review 5.  Pharmacovigilance in pharmaceutical companies: An overview.

Authors:  Maria Mammì; Rita Citraro; Giovanni Torcasio; Gennaro Cusato; Caterina Palleria; Eugenio Donato di Paola
Journal:  J Pharmacol Pharmacother       Date:  2013-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.